Displaying 1–25 of 223 results for Paul Thomas, Senior Editor
By better combining and interpreting readily available data, biomanufacturing experts are improving control of fermentation and other processes, says Sartorius Roland Bienert.
By better combining and interpreting readily available data, biomanufacturing experts are gaining better control of fermentation and other processes, says Sartorius Roland Bienert
By better combining and interpreting readily available data, biomanufacturing experts are gaining better control of fermentation and other processes, says Sartorius Roland Bienert.
Readers recognize tools that break new ground but promise to improve efficiency
Can standardization and innovation coexist?
FDAs John Kauffman describes the vast potential of portable Raman devices, even for those who are not trained spectroscopy experts.
Efforts to enact meaningful standards for single-use bioprocessing technologies move at a snail's pace, with no clear path forward, experts say.
Janet Woodcock looks forward to having more cash and resources with new user fee legislation. Meanwhile, she raises concerns about the Agencys authority over biosimilars should the Supreme Court strike down the Affordable Care Act.
To survive, Steven Burrill tells Big Pharma, ignore the gravel in the road and embrace the disruption.
Michael Donlon and Dermot Doran of Pfizer Newbridge discuss the challenges and success of the sites YOU Have the Power project.
An interview with Thomas Schilling on the companys Green IT initiative.
Drug industry environmental stewardship projects are becoming more sophisticated and challenging. Here are examples from AstraZeneca, Bayer, DSM, Pfizer, and EMD Millipore
A talk with sustainability manager Johanna Jobin about the company's new product recycling initiative.
Salary does not dictate motivation and performance.
A joint collaboration claims it has a disruptive technology that can be shipped anywhere, and used in any way. Does it raise the bar for future flexible facilities?
The company aims to leverage the expertise it has always had in-house, yet hadnt fully capitalized on with the pharma industry, says VP Christophe Couturier.
As conventional ways of making drugs give way, we will seek out these people and value their brilliance.
BioNetworks Doug Drabble says there are jobs throughout the state, though workers won't always relocate to take them.
A look at whats new for the cleanroom set.
New research indicates that biopharma manufacturers have a desire for operational excellence but are not using sophisticated methods that are commonplace in other industries.
West and Vetter look to meet the needs of parenteral manufacturers demanding new, safer syringe options.
It is worth having dreams, and worth fulfilling them, says former Novartis employee Anna Kroczak.
Pfizer director and PDA member Repetto discusses PDAs upcoming technical report and other critical issues facing SUS.
Our eighth annual Job Satisfaction and Salary Survey says the big picture is brighter, though not clearer.
Tectonic shifts are changing the way pharma workers will view loyalty and employment, says Kelly Services Alan Edwards.